News
22 July 2024
Certa Therapeutics, a biotechnology company developing precision therapies for inflammatory and fibrotic diseases, has been granted Orphan Drug Designation by the European Medicines Agency
Read more...20 July 2024
Many pharmaceuticals used in the U.S. depend on ingredients sourced from overseas, which can create challenges during supply chain disruptions or shortages, as demonstrated during the COVID-19 pandemic
Read more...Rona Therapeutics, a leading clinical-stage company specializing in nucleic acid drug research and development, has secured $35 million in Series A+ funding. This round was spearheaded by LongRiver Investments
Read more...18 July 2024
Today, Myogenica, a startup from the University of Minnesota, announced that the U.S. Food and Drug Administration has approved their Investigational New Drug application for MyoPAXon. This product, derived from induced pluripotent stem cells
Read more...18 July 2024
Scilex Holding Company has announced a Memorandum of Understanding for a collaboration agreement with ACEA, a China-based company focused on innovative treatments for high unmet needs.
Read more...17 July 2024
Cardurion Pharmaceuticals, a biotechnology company in the clinical stage, has announced a successful Series B financing round raising $260 million. Leading the round was Ascenta Capital, joined by new investors
Read more...Lexeo Therapeutics, Inc., a company specializing in genetic medicine, has shared positive interim results for LX2006 in treating Friedreich ataxia cardiomyopathy. The findings from both the Lexeo SUNRISE-FA Phase 1/2 trial
Read more...15 July 2024
Cytonics Corporation has initiated enrollment for its Phase 1 clinical trial of CYT-108, a novel variant of alpha-2-macroglobulin (A2M) aimed at addressing cartilage degradation in osteoarthritis (OA). This engineered protein targets proteases
Read more...13 July 2024
AbbVie has applied to the U.S. Food and Drug Administration and European Medicines Agency for approval of upadacitinib (RINVOQ®; 15 mg, once daily) to treat giant cell arteritis (GCA) in adults.
Read more...Tiba Biotech LLC, headquartered in Cambridge, has announced a new collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services
Read more...